Related Experiment Video

Updated: May 26, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

P2Y12 platelet inhibition in clinical practice

Peter Damman1, Pier Woudstra, Wichert J Kuijt

  • 1Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Journal of Thrombosis and Thrombolysis
|December 21, 2011
PubMed

Insights

Platelet P2Y12 inhibitors are crucial for preventing acute coronary syndrome and complications from percutaneous coronary intervention. This review examines clopidogrel

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Thrombosis Research

Background:

  • Atherothrombosis, particularly intracoronary, is a primary cause of acute coronary syndrome (ACS) and complications following percutaneous coronary intervention (PCI).
  • Platelet activation, adhesion, and aggregation are central to thrombotic processes, making their inhibition vital for managing ACS and post-PCI events.
  • The P2Y12 receptor, activated by adenosine diphosphate (ADP), is a key mediator in platelet activation, leading to glycoprotein IIb/IIIa receptor activation and sustained aggregation.

Purpose of the Study:

  • To review the pharmacological limitations of the P2Y12 inhibitor clopidogrel.
  • To describe newer P2Y12 inhibitors, prasugrel and ticagrelor.
  • To discuss the clinical implications of these novel antiplatelet agents.

Main Methods:

  • Literature review of pharmacological data and clinical trial outcomes.
  • Analysis of P2Y12 receptor antagonism and its downstream effects on platelet function.
  • Comparative assessment of clopidogrel, prasugrel, and ticagrelor efficacy and safety profiles.

Main Results:

  • Clopidogrel exhibits pharmacological limitations impacting its antiplatelet efficacy.
  • Prasugrel and ticagrelor offer alternative P2Y12 inhibition with potentially improved clinical outcomes.
  • Introduction of these newer agents has significant implications for managing patients with atherothrombotic disease.

Conclusions:

  • Novel P2Y12 inhibitors provide valuable therapeutic options beyond clopidogrel for patients with ACS and those undergoing PCI.
  • Understanding the pharmacodynamics and clinical benefits of prasugrel and ticagrelor is essential for optimizing antiplatelet therapy.
  • Further research continues to refine the role of P2Y12 inhibitors in cardiovascular disease management.

More Related Videos

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...